Oscar Health director Mario Schlosser sold Class A common stock worth approximately $30.18 million on June 23, 2026, through a Rule 10b5-1 trading plan. The sales involved both direct holdings and shares held indirectly via family trusts, following his acquisition of shares through Class B common stock conversion and option exercises. These transactions occurred amidst Oscar Health's volatile stock performance and recent analyst upgrades, and a transition in Mr. Schlosser's role within the company.

TSS, Inc.'s Chief Operating Officer, Karl Todd Marrott, surrendered 49,188 shares of common stock at $11.32 per share to fulfill tax withholding obligations related to the vesting of restricted stock. This was a non-discretionary tax-withholding disposition, not an open-market sale, and Marrott still directly holds 403,447 shares, indicating a continued significant equity position in the company. The transaction has limited signaling value regarding insider sentiment as it's a routine tax matter.

This article provides financial data for UNITIL Corporation (NYSE: UTL), specifically focusing on its forward price-to-earnings ratio. It presents the Period Value and Change/Change % for this metric. The content appears to be a stub or a section of a larger financial data overview from TradingView, lacking detailed analysis or commentary.

This page from TradingView provides a snapshot of the price to sales forward for Texas Roadhouse, Inc. (MUN:ROW). It lists the company's financial data, showing the current value and change over time for this metric. The content emphasizes that the data is "Made by humans" and sources market data from ICE Data Services and reference data from FactSet.

REGENXBIO has dosed the first patient in its phase 2b/3 NAAVIGATE clinical trial for surabgene lomparvovec (sura-vec) for diabetic retinopathy, administering the gene therapy via suprachoroidal delivery. This investigational gene therapy, developed in collaboration with AbbVie, aims to provide sustained treatment by inhibiting VEGF, with REGENXBIO receiving a $100 million milestone payment for this first dosing. The trial will evaluate the safety and efficacy of sura-vec in patients with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME), using a 1.0x10^12 GC/eye dose and targeting a >2-step improvement on the diabetic retinopathy severity scale (DRSS) at one year.

Universal Health Realty Income Trust (UHT) is a real estate investment trust specializing in healthcare properties like hospitals and medical office buildings, not a dairy company as its ticker might suggest. The article highlights UHT's focus on long-term rental income from healthcare facilities, often operated by Universal Health Services, and its history of stable dividend payments. It clarifies that UHT offers investors exposure to the healthcare real estate market, differentiating it from consumer staples.

This article provides the enterprise value to forward revenue for Vista Gold Corp. (DUS:JEJ). It appears to be a financial data point from TradingView, focusing on the company's valuation metric on the Dusseldorf Stock Exchange. The content is primarily a data placeholder within a larger financial platform.

UNITED NATURAL FOODS INC director Gloria R. Boyland reported a bona fide gift of 2,000 shares of Common Stock to a donor-advised fund, with no sale proceeds. After this transaction, Ms. Boyland directly holds 30,963 shares. The filing indicates a neutral impact and sentiment regarding this gift transfer.

This article from Investing.com is a brief notice about a Form 4 filing for VF Corporation, referring to the financial period ending June 30. It includes VFC's stock performance and is published under the 'Stock Market' news section. No specific details of the Form 4 are provided within the article.

Vishay Intertechnology Inc (VSH) shares dropped 4.4% on June 30, 2026, closing at $53.78, which is significantly above its estimated intrinsic value of $20.91 according to GuruFocus' GF Value™. The stock is deemed substantially overvalued with a GF Score™ of 59/100, indicating average investment quality but with strong profitability and very poor valuation. There have been no insider transactions in the last three months, raising questions about insider confidence.